FDA Grants Breakthrough Device Designation to Cleo Skin AI Pathology Tool
Clinical studies found improved melanoma detection sensitivity, while a small US evaluation showed a 20% reduction in slide analysis time.
Clinical studies found improved melanoma detection sensitivity, while a small US evaluation showed a 20% reduction in slide analysis time.
Gestalt and Primaa have partnered to integrate AI-powered dermatopathology tools in the PathFlow platform, enhancing skin cancer diagnostics.
DermaSensor Inc. announced FDA clearance for its real-time, non-invasive skin cancer evaluation system which detects common skin cancers.
Scientists have identified potential new biomarkers that could indicate how someone diagnosed with metastatic melanoma will respond to immunotherapy treatment.
Read MoreWhen T cells are activated they release the CXCL13 protein, which helps attract more B cells and T cells to the tumor site.
Read MoreA new patient-centered approach more accurately identifies melanoma patients eligible for sentinel lymph node biopsy (SLNB).
Read MoreDermaSensor presented a pooled analysis from clinical studies evaluating the performance of the company’s device in detecting skin cancer.
Read MoreThe U.S. General Services Administration has recommended DermTech’s foundational melanoma assay for coverage by the VHA.
Read MoreResearchers found potential biomarkers that predict the likelihood for checkpoint inhibitor drugs to cause progression of melanoma cells.
Read MoreRoche has announced the launch of the PRAME Antibody to identify PRAME protein expression with suspected melanoma.
Read MoreProscia released study results on new AI that predicts diagnostic agreement for melanoma, the deadliest form of skin cancer.
Read MoreUnilabs and Proscia have announced that the diagnostic group has chosen Proscia’s DermAI skin pathology solution.
Read MoreInterVenn’s new melanoma test is commercially available as a glycoproteomics LDT that aids oncologists in planning treatment for melanoma.
Read MoreResearchers have discovered blood biomarkers that can help identify if someone suffering from Melanoma can benefit from immune checkpoint inhibitors.
Read MoreFoundationOne CDx is used as a companion diagnostic for two groups of FDA-approved therapeutics in melanoma, which includes BRAF inhibitor monotherapies.
Read MoreResearchers used deep learning framework to transform microscopy images of intact skin into histochemically stained sections imaged on microscope slides.
Read MoreProscia has released study results on new technology that leverages AI to automatically detect melanoma with a high degree of accuracy.
Read MoreCastle Biosciences’ acquisition of CLIA-certified Myriad MyPath Laboratory from Myriad Genetics will expand its suite of genomic tests for skin cancer.
Read More